WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters.

The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to provide an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken.

WHO Drug Information is published 4 times a year and can be ordered from: Marketing and Dissemination, World Health Organization, 1211 Geneva 27, Switzerland.

Annual subscription rate: Sw.fr. 75. - surface mail (other rates available)
Price per copy: Sw.fr. 25. -
(30% reduction in price for developing countries.)

WHO Drug Information can be viewed at:
http://www.who.int/druginformation